empagliflozin (Jardiance) -

empagliflozin (Jardiance)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Diabetes
Summary
The SMC has accepted empagliflozin (Jardiance®) for restricted use within NHS Scotland for the treatment of type 2 diabetes as part of dual therapy (+metformin); triple therapy (+ metformin + standard of care); and as an add-on to insulin therapy (+ insulin +standard of care).
UKMi comment
Although empagliflozin is also indicated as monotherapy in patients who cannot tolerate metformin, the SMC is unable to recommend its use in this way as the company’s submission did not include evidence of cost-effectiveness in this setting.
Related links: